The purpose of this study is to: * Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality o…

Hereditary Transthyretin-Mediated Amyloidosis With PolyneuropathyhATTR-PN

~Estimated

~$10 – $8,750

Alnylam PharmaceuticalsNCT07223203

ConTTRibute: A Global Observational Multicenter Long-Term Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

The purpose of this study is to: * Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidos…

Transthyretin-Mediated AmyloidosisATTR Amyloidosis

~Estimated

~$10 – $1,050

Alnylam PharmaceuticalsNCT04561518